Our new stocks to buy list comes from Money Morning's Executive Editor Bill Patalon. Patalon has picked as many as 185 winners since he launched his Private Briefing investing service just three years ago.
Some of his recent recommendations, like Celldex Therapeutics (Nasdaq: CLDX), have brought gains as high as 648%. His pick Inovio Pharmaceuticals Inc. (Nasdaq: INO) brought readers a gain of 456% in just 14 months.
Patalon is a 30-year veteran analyst of business, economics, and financial markets. In his daily column for Private Briefing, he gives his readers invaluable investment advice, contrarian investing views, and the best stocks to buy to maximize gains.
He finds his stock picks from closed-door sessions with our team of investing experts and hours of analysis and research.
Here are five of the best stocks to buy that Patalon recommended this week...
Follow us on Twitter @moneymorning, and Bill Patalon @PrivateBrief.